AF
BCRX icon

Allworth Financial’s BioCryst Pharmaceuticals BCRX Stock Holding History

Allworth Financial’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.7K Buy
5,172
+4,695
+984% +$42.5K ﹤0.01% 2451
2026
Q1 		$4.54K Buy
477
+45
+10% +$349 ﹤0.01% 4020
2025
Q4 		$3.37K Sell
432
-110
-20% -$795 ﹤0.01% 3919
2025
Q3 		$4.11K Sell
542
-65
-11% -$541 ﹤0.01% 3664
2025
Q2 		$5.44K Buy
607
+234
+63% +$2.18K ﹤0.01% 3218
2025
Q1 		$3.07K Hold
373
– – ﹤0.01% 3028
2024
Q4 		$2.84K Hold
373
– – ﹤0.01% 3016
2024
Q3 		$2.83K Hold
373
– – ﹤0.01% 2813
2024
Q2 		$2.66K Sell
373
-781
-68% -$4.31K ﹤0.01% 2790
2024
Q1 		$5.86K Buy
1,154
+411
+55% +$2.31K ﹤0.01% 2342
2023
Q4 		$4.45K Buy
743
+244
+49% +$1.41K ﹤0.01% 2323
2023
Q3 		$3.53K Buy
499
+220
+79% +$1.58K ﹤0.01% 2284
2023
Q2 		$1.97K Buy
279
+121
+77% +$971 ﹤0.01% 2494
2023
Q1 		$1.32K Buy
158
+38
+32% +$366 ﹤0.01% 2568
2022
Q4 		$1.38K Hold
120
– – ﹤0.01% 2368
2022
Q3 		$2K Buy
120
+108
+900% +$1.39K ﹤0.01% 2106
2022
Q2 		$0 Buy
+12
New +$124 ﹤0.01% 2398
2018
Q2 		– Sell
-500
Closed -$2K – 939
2018
Q1 		$2K Hold
500
– – ﹤0.01% 692
2017
Q4 		$2K Hold
500
– – ﹤0.01% 648
2017
Q3 		$3K Buy
+500
New +$2.56K ﹤0.01% 622

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Allworth Financial's BCRX Position: Q2 2026 in Review

Allworth Financial increased its BioCryst Pharmaceuticals (BCRX) stake by 984% in Q2 2026, buying an estimated $42.5K and bringing the position to 5,172 shares worth $51.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2451.

Allworth Financial first reported a position in BCRX in Q3 2017 and has held it in 20 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Allworth Financial held 5,172 shares of BioCryst Pharmaceuticals worth $51.7K as of Q2 2026.
  • Allworth Financial bought 4,695 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $42.5K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #2451 holding.
  • Allworth Financial first reported a position in BioCryst Pharmaceuticals in Q3 2017 and has held it in 20 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.